Fig. 1

Differences in Δchange in mean GSM-CCA patients treated with or without sitagliptin in subgroup analysis. Differences in Δchange in mean GSM-CCA from baseline at 104 weeks in patients treated with or without sitagliptin were analyzed by the Student’s t-test. Subgroup analyses were performed in subgroups by baseline sex, age, duration of diabetes, BMI, HbA1c, presence of hypertension, presence of dyslipidemia, use of renin–angiotensin–aldosterone system inhibitors, and use of statins. Data are expressed as mean with 95% confidence interval. CI confidence interval, BMI body mass index, RAS inhibitors of renin–angiotensin–aldosterone system